Octagon Capital Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Octagon Capital Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66M	Buy	9,693,244 +833,333	+9%	+$4.93M	5.93%	7
2026 Q1	$39.6M	Hold	8,859,911	–	–	4.38%	7
2025 Q4	$48.7M	Sell	8,859,911 -207,589	-2%	-$1.01M	5.92%	4
2025 Q3	$29.7M	Sell	9,067,500 -3,525,000	-28%	-$9.98M	4.49%	7
2025 Q2	$29.1M	Buy	12,592,500 +1,892,500	+18%	+$4.11M	6.38%	4
2025 Q1	$14.9M	Buy	10,700,000 +250,000	+2%	+$418K	2.88%	12
2024 Q4	$18.1M	Buy	10,450,000 +5,877,778	+129%	+$12.2M	2.97%	12
2024 Q3	$9.19M	Hold	4,572,222	–	–	1.43%	19
2024 Q2	$10.2M	Buy	4,572,222 +1,542,222	+51%	+$4.49M	1.61%	17
2024 Q1	$8.7M	Buy	+3,030,000	New	+$6.31M	1.04%	28
2023 Q4	–	Sell	-2,777,778	Closed	-$8.78M	–	45
2023 Q3	$8.78M	Buy	+2,777,778	New	+$5.19M	1.35%	18
2021 Q3	–	Sell	-320,440	Closed	-$6.79M	–	35
2021 Q2	$6.79M	Hold	320,440	–	–	1.41%	20
2021 Q1	$6.5M	Hold	320,440	–	–	2.45%	17
2020 Q4	$8.5M	Buy	+320,440	New	+$6.9M	2.95%	14

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Octagon Capital Advisors's TSHA Position: Q2 2026 in Review

Octagon Capital Advisors increased its Taysha Gene Therapies (TSHA) stake by 9.4% in Q2 2026, buying an estimated $4.93M and bringing the position to 9,693,244 shares worth $66M. The position accounts for 5.93% of the portfolio, ranked #7.

Octagon Capital Advisors first reported a position in TSHA in Q4 2020 and has held it in 14 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Octagon Capital Advisors held 9,693,244 shares of Taysha Gene Therapies worth $66M as of Q2 2026.
Octagon Capital Advisors bought 833,333 Taysha Gene Therapies shares in Q2 2026, an estimated $4.93M.
Taysha Gene Therapies made up 5.93% of Octagon Capital Advisors's portfolio in Q2 2026, its #7 holding.
Octagon Capital Advisors first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 14 quarters since.
209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.